The fear of candidemia caused by a fluconazole-resistant species of Candida is causing many intensive care units (ICUs) to switch empiric therapy from this drug to broad-spectrum antifungal agents. We studied the epidemiology and antifungal susceptibility of Candida isolates involved in cases of candidemia among adult and pediatric patients in ICUs from 1984 to 2006. We documented 307 episodes of candidemia in 307 patients, of which only eight episodes (2.6%) were caused by a fluconazole-resistant isolate. At least three of the eight patients from whom fluconazole-resistant strains were recovered had recently received fluconazole. Overall, only 1.6% of the episodes of candidemia caused by fluconazole-resistant strains (five patients) occurred in individuals with no evidence of previous fluconazole administration. In conclusion, the use of broad-spectrum antifungal agents is not justified in ICUs with a low proportion of candidemia episodes caused by fluconazole-resistant strains of Candida.
Introduction
The incidence of candidemia in population-based studies has been estimated to be between 1.7 and 10 episodes per 100,000 inhabitants per year [1Á5] . A recent study carried out in Barcelona showed that around 33% of all episodes of candidemia occurred in patients in intensive care units (ICUs) [6] . Candidemia and invasive candidiasis have an attributable mortality close to 30% and can cause an increase in hospital spending to as much as $44,000 per episode [7, 8] .
Early and adequate antimicrobial therapy of candidemia is associated with a better outcome [9] , but therapeutic efficacy depends on the underlying antifungal resistance of the Candida species that cause the infections. Candida albicans is still the main etiological agent of candidemia, but there has recently been a significant increase in the incidence of episodes caused by non-albicans Candida species, especially C. parapsilosis, C. tropicalis, C. glabrata, and C. krusei [10] . The fear of candidemia caused by fluconazole-resistant Candida species is a factor in the decision of many ICUs to switch empirical therapy from fluconazole to broad-spectrum antifungal agents such as amphotericin B or caspofungin.
Our hypothesis is that this change in the empirical therapeutic protocols may not be justified in many ICUs where candidemia caused by fluconazole-resistant strains is uncommon. Furthermore, fluconazoleresistance can be partially predicted on the basis of prior use of azoles. We assessed the incidence of fluconazole-resistant candidemia in the ICUs of our institution, particularly in patients with no previous history of fluconazole use.
Material and methods

Institutional information and microbiological procedures
Ours is a 1,750-bed tertiary teaching hospital serving a population of approximately 750,000 inhabitants in Madrid, Spain. It includes all medical and surgical specialties, in addition to pediatrics, psychiatry, obstetrics-gynecology, and oncology and two pediatric ICUs (pediatrics and neonatology). Samples were obtained when clinically indicated. Blood specimens were processed by means of the BACTEC-9240 system (Becton Dickinson, USA). The identification of the Candida species recovered from samples was based on the phenotypic features and their biochemical characteristics as determined through the use of CHROMAgar and ID 32C (bioMérieux, Marcy-l'Etoile, France).
Patients and antifungal susceptibility testing
We retrospectively studied patients with candidemia admitted to our adult or pediatric ICUs or neonatology department from 1984 to 2006. We defined candidemia as the isolation of Candida spp. from 1 or more blood cultures. An episode of fungemia included all clinical isolates in the same admission.
Antifungal susceptibility testing was performed on all available isolates of Candida spp. (266 isolates) collected from blood samples. Fluconazole was obtained as reagent-grade powder from the manufacturer (Pfizer Pharmaceutical Group, New York, USA). The broth microdilution method was performed according to the CLSI M-27 A2 procedure (isolates recovered from 1984Á2002) [11] and by means of a different broth microdilution method (Sensititre YeastOne; Trek Diagnostic Systems, Ltd., East Grinstead, UK) (isolates collected from 2003Á2006) according to the manufacturer's instructions. The inoculated microdilution trays were incubated at 358C and read at 48 h. The MIC endpoint for fluconazole was defined as the lowest concentration producing a prominent inhibition of growth. The breakpoints of the CLSI M27-A2 protocol used to classify the isolates were as follows: susceptible 0MIC 08 mg/ml; susceptible-dose dependent, MIC 016Á32 mg/ml; and resistant 0MIC 064 mg/ml [11] .
We selected for further study those patients from whom a fluconazole-resistant strain or a strain with diminished susceptibility to fluconazole was isolated (all isolates of C. krusei, C. glabrata, or other species with an MIC ]64 mg/ml for fluconazole). The charts of these patients were reviewed and the following variables were recorded for each individual: clinical status, cause of admission to the ICU, risk factors for the development of candidemia, previous exposure to azoles during admission, antifungal treatment received, and outcome.
Results
During the study period (1984Á2006), our laboratory detected 307 episodes of candidemia in 307 patients admitted to adult or pediatric ICUs. We found mixed fungemia in 4 patients (isolation of two different species of Candida in the same blood culture). The distribution of episodes by ICU was as follows; neonatology (128), general post-surgical (50), adult (76), major heart surgery (34), and pediatric (19) . Table 1 shows the distribution of Candida spp. isolated for blood samples. Overall, 283 (92.2%) of the episodes were caused by Candida spp. that are usually uniformly susceptible to fluconazole, i.e., C. albicans, C. tropicalis, C. parapsilosis, and a miscellany of other species. The remaining 24 episodes were due to either C. glabrata (19; 6.2%) or C. krusei (5; 1.6%).
A large proportion of episodes were caused by C. parapsilosis, but the distribution of this species was not homogeneous in all units; 98 (80.3%) episodes were found in the pediatric ICU, while the remainder (19.7%) occurred in the adult ICUs. Table 2 summarizes the clinical conditions of patients with candidemia caused by Candida isolates with diminished susceptibility to fluconazole (C. glabrata) and by strains that were resistant in vitro (C. krusei and other isolates with MICs]64 mg/ml) to this antifungal. The clinical chart of one of these 24 patients was not available.
Of these patients, eight did not survive long enough to receive antifungal treatment, six received amphotericin B, three received fluconazole, one caspofungin, two fluconazole followed by one fluconazole'amphotericin B, one amphotericin B followed by fluconazole, However, only eight out of these 23 episodes (2.6% of the total number of episodes) were caused by an isolate that was intrinsically resistant or resistant in vitro to fluconazole (C. krusei or MIC ]64 mg/ml). Four out of 5 (80%) patients with candidemia caused by C. krusei died. Of the 18 patients evaluated with candidemia caused by C. glabrata, 14 (77.8%) died. The in vitro classification of these isolates was as follows; susceptible (5 or 27.8%), susceptible dose-dependent (9 or 50%), resistant (3 or 16.7%) and data not available (1 or 5.5%). Three patients received fluconazole as monotherapy, one received the combination of fluconazole and amphotericin B, one received amphotericin B followed by fluconazole, and one patient received fluconazole followed by amphotericin B. Four of the isolates causing these episodes were susceptible dosedependent and two were susceptible. Patients with susceptible dose-dependent isolates had a poor prognosis.
At least three of the eight patients from whom fluconazole-resistant strains were recovered had recently received fluconazole and/or suffered from hematological neoplasms. This means that only 5 (1.6%) of the episodes of candidemia caused by fluconazoleresistant strains occurred in patients who had not received fluconazole ( Table 2 ). The outcome of these eight patients was poor, as six died even after antifungal therapy with antifungals other than fluconazole (in two patients, death was attributable to candidemia, whereas in four death was due to different causes).
In order to assess the evolution of fluconazoleresistant strains over time, we divided our study into three periods of approximately 8 years each and calculated the proportion of episodes of candidemia caused by real in vitro resistant strains, i.e., 1984Á1991 (period 1, 0%), 1992Á1999 (period 2, 2%), and 2000Á 2006 (period 3, 3.5%). Five of the 8 episodes caused by fluconazole-resistant strains occurred in 2006. Fig. 1 shows the proportion of episodes caused by each of the relevant Candida spp. in each study period. The susceptibility to fluconazole of isolates causing candidemia decreased from 1 mg/ml in period 1 to 2 mg/ml in period 2 and to 4 mg/ml in period 3.
Discussion
Our data show that episodes of candidemia in the ICUs of our hospital are mainly caused by Candida spp. that are susceptible in vitro to fluconazole. If we focus only on microbiological data (low proportion of Candida isolates with diminished susceptibility to or even showing in vitro resistance), the widespread use of broad-spectrum antifungal agents for the empirical treatment of candidemia in our ICUs may not be justified.
A high proportion of episodes of candidemia in ICU patients occur in non-neutropenic hosts [6, 12] , and an increasing number of these episodes are now caused by non-C. albicans Candida isolates [6] . However, non-C. albicans Candida species are not necessarily resistant to fluconazole. In fact, C. parapsilosis, C. tropicalis, and many other species are almost uniformly susceptible to this antifungal. It is unusual to recover C. albicans isolates from blood that show in vitro resistance or reduced susceptibility to fluconazole and this species may be considered fluconazole-susceptible when involved in cases of candidemia [13Á17] .
Even in species that are resistant to fluconazole, such as C. glabrata, a high proportion of the isolates (90%) have an in vitro MIC below 32 mg/ml [18] . Due to the limited data from cases of candidemia caused by fluconazole-resistant isolates of C. glabarata, it is difficult to formulate any conclusions on the use of this antifungal to treat invasive candidemia caused by isolates with MICs above 32 mg/ml [18Á22]. In our opinion, patients with candidemia caused by C. glabrata should receive non-azole antifungal agents, e.g., echinocandins or amphotericin B. However, this does not infer that fluconazole as empirical treatment for invasive candidiasis would be ineffective for infections caused by C. glabrata. A retrospective study by Wilson et al. [19] showed that fluconazole was valuable in treating C. glabrata fungemia, with the elimination of the yeast from the bloodstream in 65% of their patients. It is also possible that the underlying conditions of these patients have a greater influence on prognosis than in vitro resistance of C. glabrata to fluconazole.
Guidelines from different societies and groups agree that broad-spectrum empirical coverage should be used with ICU patients with suspected invasive candidiasis, but the scientific basis for this recommendation is frequently weak, non-existent, or based on specific settings. IDSA guidelines for the treatment of invasive candidiasis recommend caspofungin or amphotericin B in cases of invasive candidiasis in unstable patients, while fluconazole should be employed for stable patients [23] . The definition of 'unstable' for ICU patients is imprecise, and often leads to massive use of broad-spectrum antifungal agents. In addition, the IDSA recommends (C-III) that patients with candidemia caused by C. glabrata be treated with high doses of fluconazole (800 mg/d).
The consequences of more widespread use of broadspectrum antifungal agents in ICU patients have not been properly evaluated, but experience in hematology units shows that massive use of fluconazole caused a shift in the emergence of non-C. albicans Candida species in these units [3] . Another example of the consequences of the overuse of broad-spectrum antifungal agents can be found in the emergence of invasive mucormycosis in some hematology units after indiscriminate prophylaxis with voriconazole [24] . In comparison with amphotericin B or caspofungin, fluconazole is better tolerated and less expensive than either of these two drugs.
In our institution, the highest number of episodes of candidemia was recorded in 2006 but the reasons for this increased incidence remain unclear. Four of the 8 cases of candidemia caused by fluconazole-resistant strains occurred during 2006. The presence of a higher proportion of fluconazole-resistant strains should be carefully monitored in the future, and the trend in the isolation of these strains over periods longer than a single year should be assessed.
It is difficult to establish the proportion of isolates that are resistant in vitro to a specific antimicrobial agent that would justify a change in empirical therapy. We believe that the incidence of 2.16% Candida strains causing invasive candidiasis in our adult and pediatric ICUs were of fluconazole-resistant does not justify replacing fluconazole with extensive broad-spectrum antifungal treatment. Moreover, we detected recent administration of fluconazole in three of the eight patients with fluconazole-resistant strains. These patients should have received a different non-azole antifungal agent.
In conclusion, the use of broad-spectrum antifungal agents is not justified in ICUs with a low proportion of candidemia episodes caused by fluconazole-resistant strains of Candida. 
